Introduction
Leishmaniasis is a group of parasitic diseases spread by two genera of sandfly and causes symptoms ranging from skin and mucous-membrane lesions (cutaneous, CL or mucocutaneous leishmaniasis, MCL) to fatal organ infestation (visceral leishmaniasis, VL). The Leishmania parasite exists in the promastigote form in the sandfly vector which is first ingested by neutrophils [1] and then by macrophages in the human host or animal reservoir [2] . It then transforms into the non-flagellated amastigote, multiplies, ruptures the macrophage and circulates to infect fresh cells. This infection may be localized in cutaneous tissue (CL) resulting in chronic lesions which may selfheal over time. Alternatively, infection of mucosae (MCL) can lead to severe tissue destruction and disfigurement while infection of the spleen, liver and bone marrow (VL) is usually fatal if not treated [3] .
Leishmaniasis is endemic in many developing countries from Central and South
America to southern Europe, the Middle East, Africa and South-West Asia and it is likely that this range will spread with altering climate patterns [4] . The number of cases has increased sharply over the last 10 years with an estimated 12 million patients. Most of these developing countries are also struggling with endemic HIV/AIDS and there has been a sharp increase in co-infection rates [5] . Both diseases attack immune cells increasing the infection risk of the other, the probability of relapse and clinical progression in both. The availability of highly active antiretroviral therapy (HAART) in Europe has led to far fewer new leishmaniasis infections in HIV-positive patients, but this treatment is only sparsely available in the majority of developing countries.
To date, the treatment of leishmaniasis has relied on toxic compounds and / or established drugs originally developed for other diseases. The first chemotherapy for newly diagnosed patients is still antimony (V) based drugs in most countries [6] .
These include sodium stibogluconate (Pentostan ® ) and meglumine antimoniate (Glucantime ® ) which are complex mixtures of oligomeric sugar -metal complexes, rather than discreet molecules [7] . The antimony (V) is reduced to more toxic trivalent antimony in the parasite although there are competing theories concerning the leishmanicidal mechanism of these compounds [8] . The antimonials require up to 28 days of parenteral administration and significant acquired drug resistance has emerged. The more expensive pentamidine and amphotericin B is usually effective in these cases, but still require injection or infusion and are beset with side-effects [9, 10] . The anti-cancer agent Miltefosine (hexadecylphosphocholine) is the first effective oral drug, although it is teratogenic, still moderately expensive and can lead to resistance if treatment is incomplete [10, 11] .
In the quest for less toxic and less expensive chemotherapies, a large number of plant extracts and plant-derived natural products have been tested for anti-protozoal activity [12] . Most of the major classes of natural products have representatives with in vitro or in vivo activity against Leishmania, including phenolic compounds, terpenoids, quinones and alkaloids. Arguably, the most promising candidates belong to the latter family which include the anti-malarial quinine, an aminoquinoline that inhibits choline transport in L. major promastigotes [13] . The 8-aminoquinoline sitamaquine is an orally available drug that showed considerable promise in preclinical models, but yielded mixed results in clinical trials, exhibiting variable cure rates and nephrotoxicity [14] . Structurally simpler 2-substituted quinolines, some isolated from the Bolivian medicinal plant Galipea longiflora (Rutaceae), show potent oral activity in a murine model of CL [15, 16] and VL [17] .
Simple quinolines could be important leads in the development of affordable, orally available treatments for leishmaniasis. Current chemotherapies and recent advances have been broadly reviewed elsewhere [18, 19] . Our purpose here is to survey the structure activity relationship (SAR) of leishmanicidal quinoline analogues. 
Monosubstituted Quinolines
A series of 2-substituted quinoline alkaloid natural products isolated from a Bolivian medicinal plant, G. longiflora, used to treat CL ulcers demonstrated potent activity against a mouse model of New World CL [15] . These structurally simple quinolines show potent oral activity against both CL [15, 16] and VL [17] . A variety of substitutions at the 2-position of the quinoline ring have been extensively studied because of the potent activity seen with isolated three -five carbon chain quinoline natural products (2-n-propylquinoline (1) , 2-(l, 2-trans-epoxypropyl) quinoline (chimanine D) (2) 2-(E)-prop-1-enylquinoline (chimanine B) (3) and 2-npentylquinoline (4)) which show greater potency than N-methylglucamine antimonate against L. amazonensis, L. braziliensis and L. donovani [20] .
Substitution of an unsaturated group at the 2-position (e.g. α,β-unsaturated aldehyde or allylic alcohol (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) ) increased in vitro activity relative to the unexpectedly potent 2-n-propylquinoline [21, 22] . Compounds 5, 8, 9, 11, 12 showed significant inhibition of L. amazonensis and L. infantum amastigote proliferation in macrophages [23] .
Analogues 5 and 9 had similar bioactivities (IC 50 = 3.6, 3.2 μM respectively) against resistant strains of L. donovani. Both 5 and 9 were approximately 3 times more active than miltefosine against the HePC-R line and 40 times more active then sitamaquine on the Sita-R line and all other Leishmania tested cell lines [24] . Increasing the chain length of the 2-substituent resulted in a dramatic decrease in leishmanicidal activity.
2-But-2-enenitrile and 2-hex-2-ene analogs, for example exhibited in vitro IC 50 = <30 μM when screened against L. donovani, L. amazoniensis and L. infantum [17, 25] .
Saquinavir (15), a 2-substituted aminoquinoline inhibits L. major parasite growth by 17% to 65% over 2 to 3 days in a dose-dependent manner. However, inhibition of L.
infantum, parasite growth was only 5% to 34% over the same period with irreversible leishmanicidal activity [26] .
By comparison, 3-substituted quinolines demonstrate limited in vitro activity against
major, L. mexicana and L. donovani) [23, 27] . Investigations of 3-substituted bisquinolines or halogenated analogues indicated that these compounds were either inactive or possessed significant cytotoxicity against host cells [23, 27] . The corresponding 5-and 6-substituted quinolines have received less attention.
Zosuquidar, a P-glycoprotein inhibitor, is a promising reversing agent against donovani amastigotes from BALB/c mouse peritoneal macrophages in vitro [32] .
Recently, 30 was shown to reduced the splenic and liver parasite burdens in L.
donovani-infected hamsters by >93.0% [33] . In addition, both 30 and the less reactive 32 proved to be 'dual inhibitors' of type I and II DNA topoisomerases of L. donovani, suggesting the possibility of rational drug design [34] . By contrast, simple 2,3-disubstituted quinolines had no leishmanicidal activity in the assays employed. 2-Methyl-3-carboxyquinoline, for example, had an in vitro IC 50 = >30 μg/mL against L.
donovani [35] .
Studies of 2,4-disubstituted quinolines are limited to 4-methoxy or carboxy quinolines with a 2-alkyl or aryl group. These derivatives were again isolated from the stem bark of G. longiflora, the extract of which is used as a traditional medicine for the treatment of CL [36] . The most potent compound was 33, which displayed in vitro [14] . Analogues of primaquine exhibit improved activity against a number of Leishmania species [49] . Analogue 57, for example, has an MEC of 10 μg/ml, compared to 100μg/ml for the parent [30] .
Trisubstituted Quinolines
Sitamaquine (WR-6026) is the most studied example of a leishmanicidal tri- hamsters, although none were as potent as the parent [55] . Replacing the diethylamino moiety with di-n-propylamino, for example, decreased the G-index (G = SD 90 for meglumine antimoniate / SD 90 for test compound) from 474 to 333. Replacing this moiety with a substituted-l-piperazine or related heterocycle resulted in a greater decrease in activity in the same assay [56] . Retaining this diethylamino group, but shortening the tether from hexyl to pentyl, or lengthening it from hexyl to heptyl, also lowered the G-index (178 and 96.8 respectively). Retaining all three substituents of sitamaquine but introducing a 2-hydroxy substituent almost completely removed activity, ruling out this derivative as an active metabolite. Extending the aromatic nucleus from quinoline to acridine had a similarly deleterious effect on leishmanicidal activity [57] .
Quinolines substituted at positions 2-, 3-and 4-are available by condensation of aniline with β-keto esters ( Figure 2) with an MIC of 6.5 μg/ml with a low level of cytotoxicity against macrophages [59] . 
Polysubstituted Quinolines
The anti-leishmanial activity of tetra-and penta-substituted quinolines has not been investigated systematically. Figure 3 ). 
Structure Activity Relationship (SAR)
A meta-analysis of the above data allows the formulation of a qualitative SAR. This task is complicated by: (i) the different models used to assess bioactivity in vitro (promastigote and amastigote) and in vivo (mouse, canine, rat and hamster models);
(ii) the different units used to quantify bioactivity (eg IC 50 reported in either g/mL or M, MEC, GI, G Index) and (iii) the unknown and possibly different molecular targets for different classes of quinolines. The SAR presented in Figure 4 is therefore only a qualitative guide. 
Preclinical and Clinical Development.
Although aspects of the mechanism of action, metabolism and toxicity of selected quinolines have been described, in general these areas of preclinical development are not well understood. This is partly due to the patchy approach to these studies. A quinoline, active against another target, and for which drug approval has been obtained, is then tested in leishmaniasis studies, but the mechanism of action is not generally pursued -it is either effective or it is not. Imiquimod, for example, has been approved for external warts in adults [69] and is a successful leishmanicide, but its mechanism of action is not fully understood. Saquinavir, an HIV-protease inhibitor has also proved ineffective against VL [70] . Progression of quinolines through preclinical studies is inconsistent with most interest on chloroquine, Imiquimod, mefloquine, primaquine, sitamaquine and a few, selected substituted quinolines. A précis of the current knowledge in this area is presented below.
It is important to note that preclinical studies have involved a variety of animal models. In mice tests, for example, mice (such as random-bred albino mice (TFW line) [71] or Balb/c mice [25] ) are infected subcutaneously on their back and median lesions scores determined. Other animals (mongrel and parasite-free beagle dogs [72] , opossums [73] and rats [74] [15, 16, 36, 75] or L.
donovani [76] . Subcutaneous treatment of L. donovani-infected BALB/c mice infected with 2 for 10 days at 0-54 mmol/kg per day resulted in 86-6% parasite suppression in the liver [76] . Oral administration of 0-54 mmol/kg of 2-npropylquinoline once daily for 5 or 10 days to L. donovani-infected mice suppressed parasite burdens in the liver by 87-8 and 99-9%, respectively [76] . In a study with L. amazonensis or L. venezuelensis infected BALB/c mice, three-carbon chain quinolines (1 and 2) were more potent than N-methylglucamine antimonate against L.
amazonensis, and other 2-substituted quinoline alkaloids such as [2-(3,4 methylenedioxy phenylethyl) quinoline, 2-(3,4-dimethoxyphenylethyl)quinoline, and 3, were as effective as the reference drug [15] . In another study, also with BALB/c mice infected with L. amazonensis or L. venezuelensis, five injections of chimanine B at intervals of 4 days reduced the lesion weight by 74% and the parasite loads in the lesion by 90% compared with the values for the group of untreated mice [16] . Other 2-substituted quinolines, 1 administered by the oral and intralesional routes, 2-phenylquinoline administered by the oral route, 4 administered by intralesional injection, and two total alkaloidal extracts of G. longiflora administered by the oral route, had intermediate effects [16] . The variable leishmanicidal activities could not be explained because the modes of action of these compounds are unknown.
However, the active 2-substituted quinolines, 1 or 3, were reported to have good absorption and to be metabolized at low levels, resulting in the choice of 3 as the lead compound [16] .
Subsequent to the above studies on 2-substituted quinolines, the development of a high-performance liquid chromatographic method for the specific determination of 1, in plasma and liver homogenates of mice was reported [77] . This method was an aid to preclinical studies and was used to determine the pharmacokinetic profile of 1 following oral administration to mice [77] . More recently, the in vivo efficacy of 2-substituted quinolines on L. amazonensis CL in BALB/c mice and on L. infantum and L. donovani visceral infection in BALB/c mice established differential efficacy [17] .
2-Substituted quinolines (where the 2 substituent was -C≡CH, -CH=CHC(O)H, -CH=CHCH 2 OH, or -CH=CHCH 2 OCH 3 ) were significantly more effective than meglumine antimoniate in reducing the parasite burden in both the liver and spleen.
Quinoline 1 and 5 at 12.5 mg/kg significantly reduced the parasite burdens in the liver by ~ 60-70%. Quinoline 5 was the most promising compound against both CL and VL. These compounds displayed double anti-leishmanial and anti-viral activities, which suggested they could be potentially used as a treatment for co-infection of Leishmania-HIV [17] .
Preclinical studies have included a range of di-, tri-and tetra-substituted quinoline derivatives that could be considered to be derivatives of the frontline, potential antileishmanial lead compounds primaquine and sitamaquine. However, there are a few notable exceptions such as an indolylquinoline [33] , Imiquimod [78] , chloroquine [79] and mefloquine [62] , which will be discussed first. An indolylquinoline derivative (2-(2''-dichloroacetamidobenzyl)-3-(3'-indolylquinoline)) has been reported to reduce the parasite burdens in the spleen and liver by >93% in L.
donovani-infected hamsters. Combination therapy of the indolylquinoline derivative with sodium antimony gluconate cured established VL in hamsters, with no residual living parasites in the livers and spleens of infected animals [33] . Chloroquine did not inhibit the multiplication of L. donovani in hamster livers when administered at 100 mg/kg/day for 12 days [79] , or L. major in TFW mice when administered at 90 mg/kg/day for 5 days [62] . These results stand in contrast to the activity observed in vitro (Section 3). In the latter study, mefloquine displayed moderate activity levels against L. major in TFW mice when administered at 70 mg/kg/day for 5 days [62] .
However, in a non-blinded, therapeutic trial conducted in Columbia, 1.25-1.5 grams of mefloquine given as a single oral dose or a dose of 250 mg a day for 5-6 days was not efficacious in the treatment of New world CL [80] , whereas a trial in Ecuador gave a cure to 68% of patients (11 patients) in four weeks or less [81, 82] . Issues such as patient compliance, early vomiting, superinfection of lesions, a potential difference in the bioavailability of the drug due to methods of manufacture, and classification of lesions at a point in time (lesion might initially enlarge before healing) complicate the direct comparison of the two mefloquine trials.
Imiquimod
Topical treatment with 5% Imiquimod cream (compared with a placebo cream) of L.
major-infected BALB/c mice significantly reduced the severity of the lesions on the footpads of the mice, with less swelling due to infection, fewer parasites, and inhibition of surface ulceration. However, as Imiquimod is unlikely to penetrate as far as the inner regions of the foot, infection was expected to spread further if treatment were stopped in this animal model [78] . Recently, clinical trials using Imiquimod, topical treatment three times a week with Imiquimod cream (5%) on patients (from Damascus) led to regression of lesions of CL after 4 weeks. However after this time clinical deterioration occurred. It was concluded that topical application of Imiquimod alone was ineffective in treating Old World CL [83] . A further two Imiquimod trials, gave more promising outcomes. In the first trial, topical treatment of the drug (over 20 days) in combination with ongoing antimonial therapy led to 57% of lesions and 50% of patients (12 patients in total) being clinically 'cured' at day 20, with 90% patients being cured at 6 months [69, 84] . In the second trial (which was a double-blind randomized trial), treatment of forty patients (in Peru) with clinical resistance to antimony, received megluamine antimoniate (20 mg/kg/day intramuscularly (IM) or intravenously (IV)) and were randomized to receive topical Imiquimod (5%). The
Imiquimod group achieved a 72% cure at 3 months versus 35% of the vehicle cream group (control group). Residual scarring was less prominent when Imiquimod was used [85] .
Primaquine
Interest in use of primaquine as an anti-leishmanical agent traces back almost forty years. Altough quite toxic, primaquine, administered in conjunction with either quinine or chloroquine, is used to treat the P. vivax and P. ovale malaria [86] , and is used if no other alternatives are effective [87] . In an initial clinical trial (Ethiopia, 1970), primaquine displayed minor efficacy (1 patient of 7 patients was cured) against diffuse CL [88] . However, an observation that the 2-benzyloxy derivative of primaquine was less toxic [89, 90] , suggested the possibility of a more effective and less toxic agent may be found and stimulated work on derivatives of primaquine. This major or L. amazonesis in random bred albino mice [62] ; and 8-amino-6-methoxy lepidine derivatives (e.g. 91-93), active against L. donovani in hamsters [93] . It was demonstrated in the latter study that the presence of a 4-methyl group on primaquine (94) analogues produced a marked enhancement in anti-leishmanial effectiveness, and that a 6-methoxy lepidine (95) bearing a 8-(6-diethylaminohexyl amino) group was also effective [93] . The quinoline derivative that possessed a 4-methyl-6-methoxy-8-(6-diethylaminohexyl amino) group was to become known as sitamaquine [93] .
Studies during the last 20 years into the improved delivery of primaquine have included use of liposome carriers [94, 95] , peptide grafted liposomes [96] , a selfgelling primaquine-gum arabic conjugate [97] , nanoparticles (typically 150 to 200 nm in size) [96, [98] [99] [100] and biodegradable microspheres (1-20 M in size) [101] . Aspects such as polymer-drug interactions, in vitro drug release and physiochemical stability and toxicity were considered in some of these studies [97, 99, 101, 102] . These delivery systems were aimed at increased effectiveness, prolonged duration of action and / or reduced toxicity of the drug. The effectiveness of the primaquine-loaded nanoparticles was 3.3 times as high as the free drug [96] , whereas microspheres were 100 times more efficient than the free drug, primaquine [101] .
Sitamaquine
Sitamaquine (formerly WR-6026) is an orally active 8-aminoquinoline in development for treatment of VL and has been reviewed elsewhere [103] . Early studies identified sitamaquine as more active against L. major in vivo (random-bred albino mice, TFW line) than in tissue culture [62] ; active in mice infected with L.
donovani [104] and active in mongrel and parasite-free beagle dogs infected with L.
d. khartoum [69] . Sitamaquine also displayed parasite suppression in the liver and spleen of opposums infected with L. donovani [85] . These results stimulated the synthesis and evaluation of a variety of 8-amino side chain analogues against L.
donovani in hamsters as well as other ring substituted quinoline analogues [55, [105] [106] [107] . Although several analogues had meglumine antimoniate indexes in excess of 300 [55] , none was superior to sitamaquine. Topical formulations of sitamaquine (anhydrous gel emulsions) did not affect lesion progression or reduce parasite burden in BALB/c mice infected with L. major [109] . Encapsulated within liposomes prior to injection into hamsters was 700 to 1800 times more effective than the control antimonial drug (meglumine antimoniate). In addition, the duration of action was prolonged, and the drug toxicity decreased [110, 111] . Similarly, N-(2-hydroxypropyl)methacrylamide (HPMA) co-polymer -NPC1161 sitamaquine conjugate containing lysosomally degradable side chains, was shown to be more effective than the free drug in BALB/c mice infected with L. donovani, indicating the potential for targeted delivery [112] .
While the mode of action of 8-aminoquinolines and sitamaquine is not yet understood. It has been suggested that 8-aminoquinolines interfere with mitochondrial respiration, possibly through interactions with ubiquinones [62] . The major metabolites of sitamaquine have been identified as the desmethyl and 4-CH 2 OH derivatives in rats and hamsters [113] , with 5-hydroxylation and side chain oxidation being important steps in the metabolic pathway [114] . The 4-CH 2 OH derivative is the major urinary metabolite in humans, however only 14% of the drug could be accounted for [114] . Analysis of the physiochemical interactions of sitamaquine were studied using phospholipids to represent a parasite membrane, the first barrier to be crossed by a drug. This study indicated that initial electrostatic interaction between positively charged sitamaquine and the negative headgroups of the anionic phospholipids was required for subsequent hydrophobic interactions between the aromatic ring of sitamaquine and the phospholipid alkyl chains which led to drug insertion into the monolayer [53] .
A major concern with the clinical development of 8-aminoquinolines, such as primaquine, is that such compounds can cause oxidant-induced hemolytic anemia with methemoglobinemia (a higher than normal level of methemoglobin, metHb, in the blood, resulting in tissue hypoxia). A subchronic study of sitamaquine in SpragueDawley rats (receiving up to 12 mg/kg/day for 13 weeks) and Beagle dogs (receiving up to 3 mg/kg/day for 13 weeks) indicated that only the highest doses caused hemolytic anemia and methemoglobinemia, along with assocated hepatoxicity. The toxic effects of sitamaquine were essentially resolved by the end of the recovery period in both species [74] .
Sitamaquine has been in development for 15 years and has attracted interest in India and the Drugs for Neglected Diseases Group [115] [116] [117] . It was initially developed at the Walter Reed Army Institute of Research for treatment of leishmaniasis, with
GlaxoSmithKline helping with the final development and FDA submission. After a pilot study in India [118] , several small phase I/II clinical trials have been run. In
Brazil 67% of patients (total patients = 95) treated with sitamaquine (2 mg/kg/day for 28 days) were cured of L. Chagasi [119] . In Kenya, 83% of patients (total patients = 46) were cured of VL when treated with sitamaquine (1.7 mg/kg/day for 28 days) [51] . Similarly, in India 81% of patients (total patients = 31) were cured of VL when treated with sitamaquine (1.5 mg/kg/day for 28 days). Sitamaquine was generally well tolerated by the patients in these studies, however side effects such as renal adverse events [101] were observed in a few subjects and this appeared to be treatmentrelated. Interpretation of these data is complicated because VL itself is associated with renal impairment. Sitamaquine has also been used in cross disease studies where a single report of the drug used in a HIV-positive patient with VL indicated that the patient responded to the use of sitamaquine [120] .
Concluding Remarks
A new treatment for VL is urgently needed. Current medicines suffer from impractical treatment regimens, emerging drug resistance, or are simply unaffordable.
Quinolines are a promising class of candidates in this respect and certain examples are potentially effective and affordable chemotherapies for this devastating disease.
Unfortunately, the molecular targets of these drugs are not known and rational drug design is further hampered by the wide variety of disease models and methods of reporting leishmanicidal efficacy. In particular, a standardized in vivo model would allow quantitative comparisons of drug potency. Nevertheless, the above metastudy provides qualitatively trends useful for further investigation.
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